In the realm of clinical research, the pursuit of pragmatic trial designs has often been hailed as a step towards greater realism and flexibility. However, as Dr. Sergey Alexeev astutely points out, this pursuit may come at a hidden cost. While these designs, such as pragmatic cluster-randomized trials, adaptive platforms, and others, promise to capture the complexities of real-world conditions, they can also introduce a degree of fragility that is not immediately apparent. The author, in collaboration with Rachael Morton, delves into this paradox, revealing how these sophisticated designs can sometimes rely on statistical assumptions that are not adequately checked or scrutinized. This is particularly evident in cluster-randomized trials, where the randomization of entire hospitals, schools, or clinics can lead to significant variations in data quality and analysis outcomes. The study reanalyzed four published trials, and in three of them, the headline findings were found to be fragile, relying heavily on specific statistical assumptions. This fragility is not a failure of the original investigators but rather a reflection of the evolution of clinical biostatistics towards more flexible models. These models, while promising efficiency, often depend on assumptions about patient correlations within a site, which can be difficult to verify. For readers and researchers, this raises a critical question: how can we ensure the reliability of findings from these pragmatic trial designs? The answer lies in a four-step framework called CARE, which emphasizes the importance of clarity in site contribution, application of robust baseline analyses, refinement of models only when justified, and evaluation by presenting both robust and refined results side by side. This framework is designed to be integrated into a standard Statistical Analysis Plan, ensuring that readers can reasonably expect to see it. The implications of this work are far-reaching, especially as regulatory bodies like the US FDA and Australian regulators consider the broader use of Bayesian methods in clinical trials. While these methods are valuable, the study warns against blindly accepting their outputs without a robust benchmark. Instead, readers are encouraged to treat fashionable trial designs as a reason for more scrutiny, not less. In essence, the pursuit of realism in clinical trials should not compromise the reliability of the findings. It is a delicate balance that requires careful consideration and a critical eye. As Dr. Alexeev concludes, the bottom line for readers is to hold the conclusions of pragmatic trials more loosely than the p-value suggests, and to demand that headline results are tested against simpler, more robust methods. This is not a call to abandon innovative trial designs, but rather a reminder that trust in these designs should not be based solely on reputation, but on rigorous scrutiny and validation.
